{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:01:04Z","timestamp":1792004464936,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-024-03378-6","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T12:42:38Z","timestamp":1726663358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY"],"prefix":"10.1186","volume":"24","author":[{"given":"Noa","family":"Krugliak Cleveland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabyasachi","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Chastek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Bancroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninfa","family":"Candela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kandavadivu","family":"Umashankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"issue":"suppl 1","key":"3378_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000506364","volume":"101","author":"MC Sulz","year":"2020","unstructured":"Sulz MC, Burri E, Michetti P, Rogler G, Peyrin-Biroulet L, Seibold F. Treatment algorithms for Crohn\u2019s disease. Digestion. 2020;101(suppl 1):43\u201357.","journal-title":"Digestion."},{"issue":"suppl 1","key":"3378_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000504092","volume":"101","author":"E Burri","year":"2020","unstructured":"Burri E, Maillard MH, Schoepfer AM, Seibold F, Van Assche G, Rivi\u00e8re P, et al. Treatment algorithm for mild and moderate-to-severe ulcerative colitis: an update. Digestion. 2020;101(suppl 1):2\u201315.","journal-title":"Digestion."},{"key":"3378_CR3","doi-asserted-by":"crossref","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel J-F. Ulcerative colitis. Lancet. 2017;389(10080):1756\u201370.","DOI":"10.1016\/S0140-6736(16)32126-2"},{"issue":"5","key":"3378_CR4","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1053\/j.gastro.2022.01.023","volume":"162","author":"N Krugliak Cleveland","year":"2022","unstructured":"Krugliak Cleveland N, Torres J, Rubin DT. What does disease progression look like in ulcerative colitis, and how might it be prevented? Gastroenterology. 2022;162(5):1396\u2013408.","journal-title":"Gastroenterology"},{"issue":"3","key":"3378_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1055\/s-0037-1602237","volume":"31","author":"RW Stidham","year":"2018","unstructured":"Stidham RW, Higgins PDR. Colorectal cancer in inflammatory bowel disease. Clin Colon Rectal Surg. 2018;31(3):168\u201378.","journal-title":"Clin Colon Rectal Surg"},{"issue":"3","key":"3378_CR6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.giec.2019.02.008","volume":"29","author":"SC Shah","year":"2019","unstructured":"Shah SC, Itzkowitz SH. Management of inflammatory bowel disease-associated dysplasia in the modern era. Gastrointest Endosc Clin N Am. 2019;29(3):531\u201348.","journal-title":"Gastrointest Endosc Clin N Am"},{"issue":"1","key":"3378_CR7","doi-asserted-by":"publisher","first-page":"e000573","DOI":"10.1136\/bmjgast-2020-000573","volume":"8","author":"PM Irving","year":"2021","unstructured":"Irving PM, de Lusignan S, Tang D, Nijher M, Barrett K. Risk of common infections in people with inflammatory bowel disease in primary care: a population-based cohort study. BMJ Open Gastroenterol. 2021;8(1):e000573.","journal-title":"BMJ Open Gastroenterol"},{"issue":"9","key":"3378_CR8","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/ajg.2012.218","volume":"107","author":"GR Lichtenstein","year":"2012","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, et al. Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREAT\u2122 registry. Am J Gastroenterol. 2012;107(9):1409\u201322.","journal-title":"Am J Gastroenterol"},{"key":"3378_CR9","doi-asserted-by":"crossref","unstructured":"Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018;155(2):337\u201346.e10.","DOI":"10.1053\/j.gastro.2018.04.012"},{"key":"3378_CR10","doi-asserted-by":"crossref","unstructured":"Feuerstein JD, Ho EY, Shmidt E, Singh H, Falck-Ytter Y, Sultan S, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s disease. Gastroenterology. 2021;160(7):2496\u2013508.","DOI":"10.1053\/j.gastro.2021.04.022"},{"issue":"5","key":"3378_CR11","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","volume":"158","author":"JD Feuerstein","year":"2020","unstructured":"Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450\u201361.","journal-title":"Gastroenterology"},{"issue":"3","key":"3378_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000500721","volume":"4","author":"P Schreiner","year":"2019","unstructured":"Schreiner P, Neurath MF, Ng SC, El-Omar EM, Sharara AI, Kobayashi T, et al. Mechanism-based treatment strategies for IBD: cytokines, cell adhesion molecules, JAK inhibitors, gut flora, and more. Inflamm Intest Dis. 2019;4(3):79\u201396.","journal-title":"Inflamm Intest Dis"},{"issue":"5","key":"3378_CR13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1177\/10600280221130450","volume":"57","author":"D Choi","year":"2023","unstructured":"Choi D, Sheridan H, Bhat S. Risankizumab-rzaa: a new therapeutic option for the treatment of Crohn\u2019s disease. Ann Pharmacother. 2023;57(5):579\u201384.","journal-title":"Ann Pharmacother."},{"issue":"7","key":"3378_CR14","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1097\/MEG.0000000000000378","volume":"27","author":"JP Gordon","year":"2015","unstructured":"Gordon JP, McEwan PC, Maguire A, Sugrue DM, Puelles J. Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn\u2019s disease: a systematic review and clinician surveys. Eur J Gastroenterol Hepatol. 2015;27(7):804\u201312.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"3378_CR15","first-page":"495","volume":"44","author":"S Khan","year":"2019","unstructured":"Khan S, Rupniewska E, Neighbors M, Singer D, Chiarappa J, Obando C. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: A systematic review. J Clin Pharm Ther. 2019;44(4):495\u2013507.","journal-title":"J Clin Pharm Ther"},{"key":"3378_CR16","doi-asserted-by":"crossref","unstructured":"Krugliak Cleveland N, Ghosh S, Chastek B, Bancroft T, Candela N, Fan T, et al. Real-world persistence of successive biologics in patients with inflammatory bowel disease: Findings from ROTARY. Inflamm Bowel Dis. 2023:1\u201312.","DOI":"10.1093\/ibd\/izad245"},{"key":"3378_CR17","unstructured":"Optum Inc. The Optum EHR offering. 2020. https:\/\/www.optum.com\/content\/dam\/optum3\/optum\/en\/landing\/ls\/DRN\/DRNProduct\/EHR-offering.pdf. Accessed 6 June 2023."},{"issue":"6","key":"3378_CR18","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382.","journal-title":"Am J Epidemiol"},{"issue":"6","key":"3378_CR19","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/ecco-jcc\/jjy004","volume":"12","author":"S Singh","year":"2018","unstructured":"Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ. Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis. J Crohns Colitis. 2018;12(6):635\u201343.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"3378_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/MIB.0000000000000979","volume":"23","author":"BE Sands","year":"2017","unstructured":"Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease in patients na\u00efve to or who have failed tumor necrosis factor antagonist therapy. Inflamm Bowel Dis. 2017;23(1):97\u2013106.","journal-title":"Inflamm Bowel Dis"},{"key":"3378_CR21","doi-asserted-by":"crossref","unstructured":"Feagan BG, Lasch K, Lissoos T, Cao C, Wojtowicz AM, Khalid JM, et al. Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17(1):130\u20138.e7.","DOI":"10.1016\/j.cgh.2018.05.026"},{"issue":"13","key":"3378_CR22","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Peyrin-Biroulet L, Loftus EV, Danese S, Colombel J-F, T\u00f6r\u00fcner M, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381(13):1215\u201326.","journal-title":"N Engl J Med"},{"key":"3378_CR23","doi-asserted-by":"publisher","first-page":"175628482311594","DOI":"10.1177\/17562848231159452","volume":"16","author":"B Bressler","year":"2023","unstructured":"Bressler B. Is there an optimal sequence of biologic therapies for inflammatory bowel disease? Therap Adv Gastroenterol. 2023;16:17562848231159452.","journal-title":"Therap Adv Gastroenterol"},{"issue":"10","key":"3378_CR24","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","volume":"15","author":"B Bressler","year":"2021","unstructured":"Bressler B, Yarur A, Silverberg MS, Bassel M, Bellaguarda E, Fourment C, et al. Vedolizumab and anti-tumour necrosis factor \u03b1 real-world outcomes in biologic-na\u00efve inflammatory bowel disease patients: results from the EVOLVE study. J Crohns Colitis. 2021;15(10):1694\u2013706.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"3378_CR25","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/MIB.0b013e31828029c0","volume":"19","author":"MW Lutgens","year":"2013","unstructured":"Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 2013;19(4):789\u201399.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"3378_CR26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12876-020-01332-w","volume":"20","author":"U Helwig","year":"2020","unstructured":"Helwig U, Mross M, Schubert S, Hartmann H, Brandes A, Stein D, et al. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn\u2019s disease patients: a German retrospective chart review. BMC Gastroenterol. 2020;20(1):211.","journal-title":"BMC Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03378-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03378-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03378-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T11:04:32Z","timestamp":1726743872000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03378-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3378"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03378-6","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,17]]},"assertion":[{"value":"23 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Guidelines for Good Pharmacoepidemiology Practice published by the International Society for Pharmacoepidemiology. This study used de-identified retrospective electronic health record data from the Optum\u00ae Research Database, therefore no specific ethical approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Noa Krugliak Cleveland served as a consultant for Arena Pharmaceuticals, Bristol Myers Squibb, and Takeda Pharmaceuticals U.S.A., Inc. Benjamin Chastek and Tim Bancroft are employees of Optum. Sabyasachi Ghosh is a former employee of Takeda Pharmaceuticals U.S.A, Inc. and has stock or stock options. Ninfa Candela and Tao Fan are employees of Takeda Pharmaceuticals U.S.A., Inc. and hold stock or stock options. Kandavadivu Umashankar is an employee of University of Illinois, Chicago, IL, USA, who was supported by a Takeda Pharmaceuticals U.S.A., Inc. fellowship at the time of the study. David T. Rubin received grant support from Takeda Pharmaceuticals U.S.A., Inc. and has served as a consultant for AbbVie, AltruBio, Arena Pharmaceuticals, Bristol Myers Squibb, Genentech\/Roche, Gilead Sciences, Iterative Scopes, Janssen Pharmaceuticals, Lilly, Pfizer, Prometheus Biosciences, Takeda, and TechLab Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"314"}}